Premium
Hepatitis B vaccine in infants from an endemic area: Long‐term anti‐HBs persistence and revaccination
Author(s) -
Yvonnet B.,
Coursaget P.,
Chotard J.,
Sarr M.,
Ndoye R.,
Chiron J. P.,
DiopMar I.
Publication year - 1987
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890220404
Subject(s) - titer , medicine , booster (rocketry) , booster dose , persistence (discontinuity) , virology , antibody , hepatitis b vaccine , hepatitis b , vaccination , pediatrics , immunology , hepatitis b virus , virus , hbsag , physics , geotechnical engineering , astronomy , engineering
Persistence of anti‐HBs in 156 Senegalese infants immunized with hepatitis B vaccine was studied for periods ranging from 2 to 6 years after booster dose administration. Six years after the booster dose, 90.4% of the infants had detectable anti‐HBs antibodies, with 78.1% having titers higher than 10 mlU/ml. The geometric mean titer was 60 mlU/ml. Females showed higher anti‐HBs values than males. In a group of 11 infants who received no booster dose, anti‐HBs antibodies were detectable 7 years after the first dose. However, the geometric mean titer was lower (26 mlU/ml). Revaccination (56 infants) led to an increase of the geometric mean titer to 469 mlU/ml 2 months later. These results show that a booster injection every 5‐6 years should provide adequate protective anti‐HBs levels in infants.